{"downloaded": true, "htmlmade": false, "full": {"id": "29380563", "source": "MED", "pmid": "29380563", "pmcid": "PMC5788875", "fullTextIdList": {"fullTextId": "PMC5788875"}, "doi": "10.1002/sctm.17-0197", "title": "CD34<sup>+</sup> Cell Transplantation Improves Right Ventricular Function in Patients with Nonischemic Dilated Cardiomyopathy.", "authorString": "Frljak S, Jaklic M, Zemljic G, Cerar A, Poglajen G, Vrtovec B.", "authorList": {"author": [{"fullName": "Frljak S", "firstName": "Sabina", "lastName": "Frljak", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Advanced Heart Failure and Transplantation Centre, UMC Ljubljana, Slovenia."}}}, {"fullName": "Jaklic M", "firstName": "Martina", "lastName": "Jaklic", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Advanced Heart Failure and Transplantation Centre, UMC Ljubljana, Slovenia."}}}, {"fullName": "Zemljic G", "firstName": "Gregor", "lastName": "Zemljic", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Advanced Heart Failure and Transplantation Centre, UMC Ljubljana, Slovenia."}}}, {"fullName": "Cerar A", "firstName": "Andraz", "lastName": "Cerar", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Advanced Heart Failure and Transplantation Centre, UMC Ljubljana, Slovenia."}}}, {"fullName": "Poglajen G", "firstName": "Gregor", "lastName": "Poglajen", "initials": "G", "authorId": {"@type": "ORCID", "#text": "0000-0003-1777-8807"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Advanced Heart Failure and Transplantation Centre, UMC Ljubljana, Slovenia."}}}, {"fullName": "Vrtovec B", "firstName": "Bojan", "lastName": "Vrtovec", "initials": "B", "authorId": {"@type": "ORCID", "#text": "0000-0002-7383-1281"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Advanced Heart Failure and Transplantation Centre, UMC Ljubljana, Slovenia."}, {"affiliation": "Stanford University School of Medicine, Stanford, California, USA."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-7383-1281"}, {"@type": "ORCID", "#text": "0000-0003-1777-8807"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "2", "volume": "7", "journalIssueId": "2644342", "dateOfPublication": "2018 Feb", "monthOfPublication": "2", "yearOfPublication": "2018", "printPublicationDate": "2018-02-01", "journal": {"title": "Stem cells translational medicine", "ISOAbbreviation": "Stem Cells Transl Med", "medlineAbbreviation": "Stem Cells Transl Med", "NLMid": "101578022", "ISSN": "2157-6564", "ESSN": "2157-6580"}}, "pubYear": "2018", "pageInfo": "168-172", "abstractText": "We investigated the effects of CD34<sup>+</sup> cell therapy on right ventricular (RV) function in patients with nonischemic dilated cardiomyopathy (DCM). We enrolled 60 patients with DCM who were randomized to CD34<sup>+</sup> cell therapy (Stem Cells (SC) Group n\u2009=\u200930), or no cell therapy (Controls, n\u2009=\u200930). The SC Group received granulocyte-colony stimulating factor, and CD34<sup>+</sup> cells were collected by apheresis and injected transendocardially. Patients were followed for 6 months. At baseline, the groups did not differ in age, gender, left ventricular ejection fraction, N-terminal probrain natriuretic peptide, or parameters of RV function. At 6 months, we found a significant improvement in RV function in the SC Group (tricuspid annular plane systolic excursion [TAPSE]: +0.44\u2009\u00b1\u20090.64 cm, p\u2009=\u2009.001; peak systolic tissue Doppler velocity of tricuspid annulus [St]: +1.5\u2009\u00b1\u20092.1 cm/s; p\u2009=\u2009.001; percent of fractional area change [FAC]: +8.6%\u2009\u00b1\u20095%, p\u2009=\u2009.01), but not in Controls (TAPSE: -0.07\u2009\u00b1\u20090.32 cm, p\u2009=\u2009.40; St: -0.1\u2009\u00b1\u20091.2 cm/s; p\u2009=\u2009.44; FAC: -1.2%\u2009\u00b1\u20093.2%, p\u2009=\u2009.50). On repeat electroanatomical mapping, we found an improvement in interventricular septum viability in 19 of 30 patients from the SC Group; this correlated with the improvements in RV function (13/19 in the improved septum group versus 3/11 in the remaining cohort, p\u2009=\u2009.029). These results suggest that patients with DCM, changes in RV function correlate with changes of viability of interventricular septum. CD34<sup>+</sup> cell therapy appears to be associated with improved right ventricular function in this patient cohort. (Clinical Trial Registration Information: www.clinicaltrials.gov; NCT02248532). Stem Cells Translational Medicine 2018;7:168-172.", "affiliation": "Advanced Heart Failure and Transplantation Centre, UMC Ljubljana, Slovenia.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Randomized Controlled Trial", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Myocardium", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Heart Septum", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Heart Ventricles", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Stem Cells", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Cardiomyopathy, Dilated", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Natriuretic Peptide, Brain", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Granulocyte Colony-Stimulating Factor", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antigens, CD34", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Echocardiography", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Stroke Volume", "meshQualifierList": {"meshQualifier": {"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Cell Transplantation", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Prospective Studies"}, {"majorTopic_YN": "N", "descriptorName": "Ventricular Function, Left", "meshQualifierList": {"meshQualifier": {"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Ventricular Function, Right", "meshQualifierList": {"meshQualifier": {"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Heart Failure", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Cell- and Tissue-Based Therapy", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}]}, "keywordList": {"keyword": ["Dilated cardiomyopathy", "Right ventricular function", "Heart Failure", "Cd34+ Cells"]}, "chemicalList": {"chemical": [{"name": "Granulocyte Colony-Stimulating Factor", "registryNumber": "143011-72-7"}, {"name": "Natriuretic Peptide, Brain", "registryNumber": "114471-18-0"}, {"name": "Antigens, CD34", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1002/sctm.17-0197"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5788875"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5788875?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "4", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc-nd", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-09-11", "dateOfCreation": "2018-01-31", "firstIndexDate": "2018-01-31", "fullTextReceivedDate": "2020-07-12", "dateOfRevision": "2019-09-11", "firstPublicationDate": "2018-02-01"}, "htmllinks": "https://europepmc.org/articles/PMC5788875", "abstract": "We investigated the effects of CD34<sup>+</sup> cell therapy on right ventricular (RV) function in patients with nonischemic dilated cardiomyopathy (DCM). We enrolled 60 patients with DCM who were randomized to CD34<sup>+</sup> cell therapy (Stem Cells (SC) Group n\u2009=\u200930), or no cell therapy (Controls, n\u2009=\u200930). The SC Group received granulocyte-colony stimulating factor, and CD34<sup>+</sup> cells were collected by apheresis and injected transendocardially. Patients were followed for 6 months. At baseline, the groups did not differ in age, gender, left ventricular ejection fraction, N-terminal probrain natriuretic peptide, or parameters of RV function. At 6 months, we found a significant improvement in RV function in the SC Group (tricuspid annular plane systolic excursion [TAPSE]: +0.44\u2009\u00b1\u20090.64 cm, p\u2009=\u2009.001; peak systolic tissue Doppler velocity of tricuspid annulus [St]: +1.5\u2009\u00b1\u20092.1 cm/s; p\u2009=\u2009.001; percent of fractional area change [FAC]: +8.6%\u2009\u00b1\u20095%, p\u2009=\u2009.01), but not in Controls (TAPSE: -0.07\u2009\u00b1\u20090.32 cm, p\u2009=\u2009.40; St: -0.1\u2009\u00b1\u20091.2 cm/s; p\u2009=\u2009.44; FAC: -1.2%\u2009\u00b1\u20093.2%, p\u2009=\u2009.50). On repeat electroanatomical mapping, we found an improvement in interventricular septum viability in 19 of 30 patients from the SC Group; this correlated with the improvements in RV function (13/19 in the improved septum group versus 3/11 in the remaining cohort, p\u2009=\u2009.029). These results suggest that patients with DCM, changes in RV function correlate with changes of viability of interventricular septum. CD34<sup>+</sup> cell therapy appears to be associated with improved right ventricular function in this patient cohort. (Clinical Trial Registration Information: www.clinicaltrials.gov; NCT02248532). Stem Cells Translational Medicine 2018;7:168-172.", "Keywords": ["Dilated cardiomyopathy", "Right ventricular function", "Heart Failure", "Cd34+ Cells"], "pdflinks": "https://europepmc.org/articles/PMC5788875?pdf=render", "journaltitle": "Stem cells translational medicine", "authorinfo": ["Frljak S", "Jaklic M", "Zemljic G", "Cerar A", "Poglajen G", "Vrtovec B"], "title": "CD34<sup>+</sup> Cell Transplantation Improves Right Ventricular Function in Patients with Nonischemic Dilated Cardiomyopathy."}